Trial Profile
An Open-label Phase II Pilot Study of Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Darunavir/ritonavir (Primary) ; Nevirapine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MONOGEST
- 30 May 2023 Results (n=89) assessing the proportion maintaining a viral load (VL) of <50 copies/mL up to delivery on darunavir/ritonavir monotherapy, without requiring treatment intensification published in the Journal of Antimicrobial Chemotherapy
- 05 Aug 2021 Status changed from active, no longer recruiting to completed.
- 27 Jul 2020 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.